Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Agios Pharmaceuticals (AGIO) Revenue (2016 - 2025)

Agios Pharmaceuticals' Revenue history spans 13 years, with the latest figure at $20.0 million for Q4 2025.

  • For Q4 2025, Revenue rose 86.09% year-over-year to $20.0 million; the TTM value through Dec 2025 reached $54.0 million, up 48.03%, while the annual FY2025 figure was $54.0 million, 48.03% up from the prior year.
  • Revenue reached $20.0 million in Q4 2025 per AGIO's latest filing, up from $12.9 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $20.0 million in Q4 2025 to a low of $832000.0 in Q1 2022.
  • Average Revenue over 4 years is $8.2 million, with a median of $7.8 million recorded in 2023.
  • Peak YoY movement for Revenue: surged 574.16% in 2023, then rose 6.56% in 2025.
  • A 4-year view of Revenue shows it stood at $4.3 million in 2022, then surged by 64.8% to $7.1 million in 2023, then skyrocketed by 51.06% to $10.7 million in 2024, then soared by 86.09% to $20.0 million in 2025.
  • Per Business Quant, the three most recent readings for AGIO's Revenue are $20.0 million (Q4 2025), $12.9 million (Q3 2025), and $12.5 million (Q2 2025).